Actively Recruiting
Electrochemotherapy-Induced Changes in Tumor Microenvironment in Cutaneous Melanoma
Led by Institute of Oncology Ljubljana · Updated on 2026-02-19
150
Participants Needed
1
Research Sites
160 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Cutaneous melanoma frequently develops cutaneous and subcutaneous metastases, which may cause significant morbidity and negatively affect quality of life. Electrochemotherapy (ECT) is an established local treatment modality for cutaneous and subcutaneous tumor lesions that combines the administration of cytotoxic drugs with the application of electric pulses to increase drug uptake into tumor cells. In addition to its direct cytotoxic effects, electrochemotherapy may induce changes in the tumor microenvironment, including immune cell infiltration, vascular alterations, and other biological responses that could influence tumor control. The aim of this study is to evaluate changes in the tumor microenvironment of cutaneous and subcutaneous melanoma metastases following electrochemotherapy with either intravenous bleomycin or intratumoral cisplatin. Tumor tissue samples collected before and after treatment will be analyzed to characterize microenvironmental changes and to compare treated and untreated lesions. The results of this study may improve understanding of biological effects of electrochemotherapy in melanoma metastases and support further development of treatment strategies.
CONDITIONS
Official Title
Electrochemotherapy-Induced Changes in Tumor Microenvironment in Cutaneous Melanoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Histologically confirmed cutaneous melanoma
- Presence of cutaneous and/or subcutaneous metastases eligible for electrochemotherapy
- Candidate for electrochemotherapy with intravenous bleomycin or intratumoral cisplatin according to standard clinical practice
- Ability to provide written informed consent
You will not qualify if you...
- Contraindication to electrochemotherapy or study drugs (bleomycin or cisplatin)
- Pregnancy or breastfeeding
- Severe comorbidities preventing electrochemotherapy
- Inability to comply with study procedures
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institute of Oncology Ljubljana
Ljubljana, Slovenia, 1000
Actively Recruiting
Research Team
K
Klavdija Korošec
CONTACT
N
Neža Gros
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here